SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.17 CNY | -0.08% |
|
+1.42% | +24.31% |
| 06:08am | Shanghai Shyndec Pharmaceutical Gets Drug Registration for Eye Drops | MT |
| Nov. 27 | Shanghai Shyndec Pharmaceutical Passes Drug Evaluation for Calcium Gluconate Injection | MT |
Summary: Shanghai Shyndec Pharmaceutical Co., Ltd.
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Highlights: Shanghai Shyndec Pharmaceutical Co., Ltd.
- The company's profit outlook over the next few years is a strong asset.
- The company is one of the best yield companies with high dividend expectations.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses: Shanghai Shyndec Pharmaceutical Co., Ltd.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
Ratings Chart: Shanghai Shyndec Pharmaceutical Co., Ltd.
Source: Surperformance
| Composite Fundamentals | Composite Valuation | Composite Momentum | Capi. ($) | ||
|---|---|---|---|---|---|
| 2.24B | |||||
| 64.72B | |||||
| 8.46B | |||||
| 6.28B | |||||
| 6.18B | |||||
| 5.73B | |||||
| 3.28B | |||||
| - | 2.06B | ||||
| Average | 12.37B | ||||
| Weighted average by Cap. |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 600420 Stock
- Ratings Shanghai Shyndec Pharmaceutical Co., Ltd.